Home
About Us
R&D
Partners
Join Us
Contact Us
中文
English
Home
中文
English
About Us
Company Profile
Company Culture
Core Team
Company News
R&D
Pipeline
Platform
Partners
Join Us
Chief Medical Officer
Medical Director
Project Manager
Project Leader
Project Specialist
Contact Us
ABOUT
About us
>>
Company Profile
Company Culture
Core Team
Company News
Company News
Home>
About Us
>
Company News
NeuPharma Announces CDE Grants Breakthrough Therapy Designation to BRAF V600E Inhibitor RX208
Date:2023-04-10
Suzhou, China –
Arpil 10
more>>
NeuPharma Announces CDE Grants Breakthrough Therapy Designation to BRAF V600E Inhibitor RX208
2023-04-10
NeuPharma Announces First Patient Dosed in Phase II Clinical Trial of Novel Na+/K+-ATPase Inhibitor RX108 for the Treatment of Hepatocellular Carcinoma (HCC)
2022-11-08
NeuPharma Announces First Patient Dosed in the Phase 2 Clinical Trial in LCH/ECD of BRAF Inhibitor RX208 (HLX208)
2022-01-28
NeuPharma Announces a Collaboration with Henlius on a BRAF V600E Inhibitor RX208
2021-05-12
NeuPharma Announces First Patient Dosed in Phase II Clinical Trial of Novel Na
+
/K
+
-ATPase Inhibitor RX108 for the Treatment of Glioblastoma Multiforme (GBM)
2020-08-05
NeuPharma Announces First Patient Dosed in Phase II Clinical Trial of Novel Na
+
/K
+
-ATPase Inhibitor RX108 for the Treatment of Head and Neck Cancer
2020-07-28
NeuPharma Announces First Subject Dosed in Phase I Clinical Trial of RX208 in Patients with Advanced Solid Tumors Harboring BRAF V600E Mutation
2019-12-23
<
1
2
>